Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Pazopanib is an inhibitor of the vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor and stem cell receptor c-Kit, and has been approved for the treatment of renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazo...

Descripción completa

Detalles Bibliográficos
Autores principales: Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563343/
https://www.ncbi.nlm.nih.gov/pubmed/28185218
http://dx.doi.org/10.1007/s40262-017-0510-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563343/
https://www.ncbi.nlm.nih.gov/pubmed/28185218
http://dx.doi.org/10.1007/s40262-017-0510-z

Ejemplares similares